YUHSpace: Dept. of Internal Medicine (내과학교실)

YUHSpace

BROWSE

YUHSpace1. College of Medicine (의과대학)Dept. of Internal Medicine (내과학교실)

Dept. of Internal Medicine (내과학교실)

Researcher List

Keyword Cloud

Journal Categories

Highly Cited Articles

Trastuzumab in combination with chemotherapy versus chemotherapy alone f...

Yung-Jue Bang ; Eric Van Cutsem ; Andrea Feyereislova ; Hyun C Chung ; Lin Sh... LANCET, Vol.376(9742) : 687-697, 2010

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Jean-Charles Soria ; Yuichiro Ohe ; Johan Vansteenkiste ; Thanyanan Reungwetw... NEW ENGLAND JOURNAL OF MEDICINE, Vol.378(2) : 113-125, 2018

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

S.J. Antonia ; A. Villegas ; D. Daniel ; D. Vicente ; S. Murakami ; R. Hui ; ... NEW ENGLAND JOURNAL OF MEDICINE, Vol.377(20) : 1919-1929, 2017

This table browses all dspace content
Issue Date	Title	Journal Title
2025	Disagreement on estimating cause of death under tuberculosis treatment between the national tuberculosis registry and statistics data in South Korea, 2011-2020	JOURNAL OF INFECTION AND PUBLIC HEALTH
2025	Dynamic Response of Musclin, a Myokine, to Aerobic Exercise and Its Interplay With Natriuretic Peptides and Receptor C	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
2025	One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn’s Disease: The K-STAR Study	INFLAMMATORY BOWEL DISEASES
2025	Microarray Patch Based Transdermal Allergen Immunotherapy Prevents Gliadin-induced Anaphylaxis in a Murine Model	ALLERGY ASTHMA & IMMUNOLOGY RESEARCH
2025	Metabolic Disorders and Inflammatory Bowel Diseases	GUT AND LIVER
2025	Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib	ANNALS OF ONCOLOGY
2025	Automated, Standardized, Quantitative Analysis of Cardiovascular Borders on Chest X-Rays Using Deep Learning	JACC. Advances
2025	Sex related coronary plaque progression patterns among patients with family history as the sole cardiovascular risk factor: A PARADIGM sub-study	ATHEROSCLEROSIS
2025	Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer	MOLECULAR CANCER
2025	Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC	ONCOLOGIST
2025	Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial	ESMO OPEN
2025	Prospective external validation of a deep-learning-based early-warning system for major adverse events in general wards in South Korea	ACUTE AND CRITICAL CARE
2025	Hospitalization among adults with chronic kidney disease: results from the KoreaN cohort study for Outcomes in patients With Chronic Kidney Disease (KNOW-CKD) study	KIDNEY RESEARCH AND CLINICAL PRACTICE
2025	A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours	BMJ OPEN
2025	Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial	BMC MEDICINE
2025	Association of systolic blood pressure with incident chronic kidney disease estimated by marginal structural model: a nationwide population-based study	KIDNEY RESEARCH AND CLINICAL PRACTICE
2025	Interaction between age and therapeutic approach on outcome in older patients with patent foramen ovaleassociated stroke	REVISTA ESPANOLA DE CARDIOLOGIA
2025	Blood pressure management based on infarct volume after successful endovascular thrombectomy	EUROPEAN STROKE JOURNAL
2025	Efficacy and safety of rituximab biosimilar (DRL_RI) versus MabThera® in low-tumor-burden follicular lymphoma: the FLINTER study	THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2025	Reply to: "Comment on "Lower incidence of hepatocellular carcinoma with tenofovir alafenamide in chronic hepatitis B: Evidence from a large-scale cohort	JHEP REPORTS